Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Expanded Access With Trappsol Cyclo for an Individual Patient With Late Onset Alzheimer's Disease

Trial Profile

Expanded Access With Trappsol Cyclo for an Individual Patient With Late Onset Alzheimer's Disease

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 13 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hydroxypropyl betadex (Primary)
  • Indications Alzheimer's disease
  • Focus Expanded access; Therapeutic Use
  • Sponsors CTD Holdings
  • Most Recent Events

    • 13 Aug 2019 Results presented in a CTD Holdings media release.
    • 13 Aug 2019 According to a CTD Holdings media release, the company has filed supporting data for the patent application titled Methods for Treating Alzheimers Disease.The data filed with the US Patent and Trademark Office are from a single patient suffering from Alzheimers Disease who has been intravenously using Trappsol Cyclo, a proprietary hydroxypropyl beta cyclodextrin, for one year.The patient is using the drug on an expanded access basis.
    • 11 Jul 2019 According to a CTD Holdings media release, Company had obtained a Right of Reference letter to IND 138423, for this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top